Akèy › Distrofi Miskilè Duchenne
Etid klinik pou Distrofi Miskilè Duchenne ap rekrite nan Etazini
26 etid pou Distrofi Miskilè Duchenne ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Little Rock, AR7 etid
- Boston, MA5 etid
- Washington, DC5 etid
- Durham, NC5 etid
- Chicago, IL5 etid
- Sacramento, CA5 etid
- Gainesville, FL5 etid
- Columbus, OH4 etid
- Nashville, TN4 etid
- Seattle, WA3 etid
- Portland, OR3 etid
- Mountain View, CA3 etid
- St. Louis, MO3 etid
- Cincinnati, OH3 etid
- Los Angeles, CA3 etid
- Norfolk, VA3 etid
Pa eta
- Arkansas7 etid
- Distrik Columbia5 etid
- Florid5 etid
- Illinois5 etid
- Kalifòni6 etid
- Massachusetts5 etid
- Missouri3 etid
- New York4 etid
- North Carolina6 etid
- Ohio5 etid
- Oregon3 etid
- Pennsylvania4 etid
- Tennessee4 etid
- Texas5 etid
- Virginia4 etid
- Washington3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
Ap rekriteFaz 3
Laj 7 a 11 · Gason · Mizajou Sep 28, 2026 · NCT07160634Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
Ap rekriteEtid obsèvasyon
Laj 2 ak plis · Gason · Mizajou Sep 24, 2026 · NCT06564974A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
Ap rekriteFaz 1
Laj 2 ak plis · Gason · Mizajou Sep 11, 2026 · NCT04626674Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
Ap rekriteFaz 1
Laj 8 a 18 · Gason · Mizajou Aug 24, 2026 · NCT07172971The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy
Ap rekriteEtid obsèvasyon
0 Days – 3 Years · Gason · Mizajou Aug 19, 2026 · NCT07092540Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
Ap rekrite
Laj 6 ak plis · Gason · Mizajou Aug 17, 2026 · NCT07766980Once Weekly Infant Corticosteroid Trial for DMD
Ap rekriteFaz 4
1 Month – 30 Months · Gason · Mizajou Aug 14, 2026 · NCT05412394Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 28, 2026 · NCT07674758A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Ap rekriteFaz 1/2
Laj 0 a 17 · Gason · Mizajou Jul 8, 2026 · NCT06138639A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy
Ap rekriteEtid obsèvasyon
Laj 6 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT07127978PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
Ap rekriteFaz 1/2
Laj 2 a 7 · Gason · Mizajou Jun 23, 2026 · NCT07429240Duchenne Electronic Health Record Study
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 27, 2026 · NCT07609394Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Ap rekriteFaz 3
Laj 4 a 18 · Gason · Mizajou May 27, 2026 · NCT07608432Wearable Technology to Evaluate Hyperglycemia and HRV in DMD
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 10 ak plis · Gason · Mizajou May 22, 2026 · NCT06124196Vasodilator and Exercise Study for DMD (VASO-REx)
Ap rekriteFaz 2
Laj 6 ak plis · Gason · Mizajou May 15, 2026 · NCT06290713The Duchenne Registry
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 8, 2026 · NCT02069756Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 5 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT06839469Urinary Titin Biomarker in DMD
Ap rekriteVolontè an sante akeyi
Laj 2 a 10 · Gason · Mizajou Apr 8, 2026 · NCT07332013Trial of Cell Based Therapy for DMD
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 4, 2026 · NCT06692426Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Ap rekriteFaz 1/2
Laj 4 a 18 · Gason · Mizajou Dec 15, 2025 · NCT04906460Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy
Ap rekriteEtid obsèvasyon
Laj 5 ak plis · Tout sèks · Mizajou Nov 24, 2025 · NCT05016908Biomarker Development for Muscular Dystrophies
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 5 ak plis · Tout sèks · Mizajou Nov 24, 2025 · NCT05019625Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim
Ap rekriteEtid obsèvasyon
Laj 10 ak plis · Gason · Mizajou Nov 6, 2025 · NCT06093100Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 5 a 62 · Gason · Mizajou Oct 15, 2025 · NCT01484678DMD Voice: Qualitative Interviews With Patients and Caregivers
Ap rekriteEtid obsèvasyon
Laj 10 ak plis · Gason · Mizajou Apr 30, 2025 · NCT06925269Sous ClinicalTrials.gov, done yo ranmase Oct 3, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.